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ABSTRACT 
The ability of tumors to induce angiogenesis, or new blood vessel 
formation, is critical to their growth and spread. As a result, factors which 
inhibit angiogenesis are targets for cancer therapy. One anti-angiogenic agent, 
TNP 470, is derived from a compound, fumagillin, which induces cell cycle 
arrest specifically in endothelial cells. Fumagillin has been shown to inhibit 
the action of a metalloprotease, methionine aminopeptidase-2 (MetAP-2), 
which is found in both endothelial and non-endothelial cell types. A crystal 
structure of MetAP-2 with bound fumagillin has recently been solved, which 
suggests that there are several residues of MetAP-2 in close approximation to 
fumagillin. These residues may be important in determining specificity of the 
drug for this enzyme. It was thus hypothesized that by mutating these 
residues using site-directed mutagenesis, it may be possible to generate 
mutant versions of MetAP-2 resistant to fumagillin binding. The results 
presented here demonstrate that three such mutations, G341D, G341S, H339F 
have been identified. These mutations confer resistance to 10 nM, 5nM, and 
InM concentrations of fumagillin, respectively, which would normally 
inhibit wild type MetAP-2. If endothelial cells expressing these mutations are 
resistant to the cell-cycle arrest normally induced by this drug, it constitutes 
significant functional evidence that the anti-angiogenic effect of this drug can 
be attributed to its specific interaction with MetAP-2. 
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INTRODUCTION 
Angiogenesis 
Angiogenesis can be defined as growth of new microvessels (1). This 
process is dependent on the proliferation of capillary endothelial cells. These 
cells normally divide very slowly, with turnover times on the order of 
hundreds of days, and therefore define a relatively quiescent tissue (2). 
However, when stimulated appropriately, these cells can emerge from this 
quiescent state and undergo brief periods of rapid division. An example of 
this type of angiogenesis occurs in the ovarian follicle, in which there is a 
burst of capillary vessel growth which lasts a few days, and is then turned off. 
Pathologic angiogenesis occurs when the process of angiogenesis 
continues to occur for long periods of time, on the order of months to years. 
An example of this process occurs in tumor growth. In 1974, Folkman 
hypothesized that in the absence of vascularization, the size and growth of 
tumors is limited (3). He suggested that there are several "microtumors" 
developing at any given time in the human body, which never develop into 
detectable tumors due to lack of adequate supply of oxygen and nutrients. At 
some point in tumor development, however, these microtumors develop the 
ability to induce the formation of new blood vessels. These new vessels 
provide nutrients and oxygen, and act as conduits through which metastases 
can spread. Although the exact mechanism is unclear, several studies have 
supported this hypothesis (4). As a result, a new target of cancer therapy has 
been the development of agents which can selectively inhibit this angiogenic 
process, thereby returning microtumors to their equilibrium resting state. 
This is the fundamental goal of anti-angiogenic cancer therapy. 

Abraham, John Page 5 
Fumagillin/TNP-470 
In 1990, it was shown by D. Ingber that a fungal contaminant, 
Aspergillus fumigatus fresenius, inhibits growth of capillary endothelial cells 
in culture (5). The active compound secreted by the fungus is fumagillin 
(Figure 1). A non-toxic synthetic analog of fumagillin, AGM-1470 
(Angiogenesis Modulator-1470) has been shown to inhibit capillary 
endothelial cell growth at picomolar concentrations in vitro (6). The clinical 
preparation is synthesized by Takeda Pharmaceutical Company and called 
Takeda Neoplastic Product-470, or TNP-470. TNP-470 is a more potent 
inhibitor of capillary endothelial cell division than fumagillin and has 
demonstrated little toxicity in studies to date (7-10). Systemic administration 
of TNP-470 have been shown to inhibit tumor growth in mice, rats, and 
rabbits, although in vivo tumor inhibition requires higher concentrations 
than in vitro cell culture assays (11-14). 
The exact mechanism of action of TNP-470 is unknown. However, it 
has been shown to specifically induce arrest of endothelial cells in the late G[ 
phase of the cell cycle (15). TNP-470 results in the inhibition of the 
retinoblastoma gene product phosphorylation as well as inhibition of cyclin 
dependent kinases cdk2/4 and expression of cyclins E and A (15). It is known 
that the late G] arrest is not a result of perturbation of early signaling events, 
since addition of the agent 3 hours after stimulation with growth factor still 
results in full arrest (15). 
Initial explorations into the mechanism of action of TNP-470 revealed 
that the agent binds covalently to an enzyme, Methionine Aminopeptidase-2 
(MetAP-2) , which was initially identified biochemically based on its ability to 
cleave the amino-terminal methionine residue from peptide substrates (16). 
This enzyme is found in both endothelial and non-endothelial cells (17), 
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although the inhibition of the cell cycle has been shown to exhibit specificity 
to endothelial cell types for unknown reasons (18). 
Methionine Aminopeptidases 
Members of the methionine aminopeptidase (MetAP) family are cobalt 
dependent metalloproteases, which function in the selective cleavage of 
methionine from the amino terminus of peptides and proteins in a non- 
processive manner (19). Based on sequences comparisons, it has been 
proposed that two distinct MetAP families exist, MetAP-1 and MetAP-2 (20). 
Studies in isogenic yeast strains differing only in the presence or absence of 
functional MetAP-1 or MetAP-2 have shown that fumagillin binds selectively 
to, and specifically and irreversibly inhibits, MetAP-2 in vivo (16). 
There is evidence that MetAP-2 serves a critical role in cell growth in 
addition to its housekeeping function. Experiments in S. cerevisiae have 
shown that deletion of either MetAP-1 or MetAP-2 results in viable, slow- 
growing yeast. Deletion of both genes results in a lethal phenotype (21). 
MetAP-2 expression has been shown to correlate with cell growth. In 
quiescent cells, MetAP-2 levels are below the level of detection using standard 
immunologic methods. Upon addition of a mitogen, the protein levels 
increase greatly (22). MetAP-2 has also been identified as a 67kDa protein 
associated with cell cycle factor eIF-2, and partially reverses protein synthesis 
inhibition mediated by phosphorylation of eIF-2 in vivo (23). It is unlikely 
that TNP-470 cell cycle arrest is due to interruption of this interaction, because 
the general protein synthesis inhibition that would result is not compatible 
with the 7-fold induction in E-selectin protein levels that is seen upon TNP- 
470 addition (24). 
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Crystal Structure of Fumagillin-bound MetAP-2 
Although the binding to and inhibition of MetAP-2 by fumagillin is 
well documented, this does not constitute satisfactory evidence that the anti- 
angiogenic property of fumagillin is due to this interaction. In order to 
further define the interaction, a 1.8 angstrom resolution crystal structure has 
recently been solved for human MetAP-2 alone and bound to fumagillin (25). 
The crystallographic data has shown that human MetAP-2 has a central [3 
sheet with an active site located approximately at the center of its concave 
face. Two pairs of a-helices and a short COOH-terminal tail cover the sheet's 
concave face (Figure 2). The active site is a deep pocket with two cobalt 
molecules at its base, and another pocket that presumably serves as the 
specificity pocket for the amino-terminal methionine side chain of neutral 
substrates. Reorientation of the Tyr444 side chain and some water molecules 
opens this pocket to solvent. This Tyr444 residue is completely conserved in 
the MetAP-2 family across species. 
Molecular Interactions Between MetAP-2 and Fumagillin 
The irreversible inhibition of MetAP-2 by fumagillin is the result of a 
covalent bond formed by an imidazole nitrogen atom of His231 of MetAP-2, 
and the carbon of the spirocyclic epoxide of fumagillin (16). His231 is believed 
to be important for the catalytic activity of the enzyme, as an electrophile in 
an acid-base catalytic triad. The residue does not move significantly with this 
bond formation, as its nucleophilic imidazole is perfectly positioned to bond 
with the methylene of the epoxide. The only molecule that moves upon 
fumagillin binding of MetAP-2 is His339, which rotates its side chain to avoid 
close contacts with fumagillin (Figure 3). These amino acid residues are 
therefore critical to fumagillin binding. In addition, several residues are 
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identified by this crystal structure which are in close approximation to bound 
fumagillin. These residues include Tyr444, Phe219, lle338, and His331 (Figure 
4). These residues form hydrophobic interactions with the molecule in the 
deep pocket near the active site of the enzyme. Additionally, the long 
unsaturated side chain of fumagillin is directed out of the binding pocket and 
makes two hydrophobic contacts with Leu328 and Leu447, both of which are 
conserved within the MetAP-2 family (Figure 5) (25). 
Relevance of Crystallographic Data 
The crystal structure of MetAP-2 bound to fumagillin has allowed 
careful analysis of the active site and the deep pocket located near the active 
site. Using this information, it may be possible to identify those residues 
which are essential in creating a localized environment in the enzyme which 
is amenable to the binding of fumagillin. Using a rational approach based on 
these data, an attempt may be made to alter these putatively critical residues 
of MetAP-2 in order to decrease the affinity with which fumagillin binds the 
enzyme. MetAP-2 mutations made using this approach may be useful as an 
initial step in the clarification of the exact mechanism of fumagillin induced 
cell cycle arrest in endothelial cells. Specifically, MetAP-2 mutations that 
allow cell viability but have reduced affinity for fumagillin may be tested for 
the response to a known inhibitory concentration of fumagillin in an 
endothelial cell system. Demonstration of a reduced potential of fumagillin to 
induce cell cycle arrest would suggest that MetAP-2 is a critical point in the 
molecular anti-angiogenic mechanism of the drug. Further clarification of the 
role of MetAP-2 in the cell may then allow generation of more potent anti- 
angiogenic compounds which may prove clinically useful. 
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Summary 
Fumagillin and its derivatives are potent anti-angiogenic compounds. 
It has been shown that these molecules bind and inhibit an enzyme 
Methionine Aminopeptidase-2, a cobalt metalloprotease. There are two 
members of the Methionine Aminopeptidase family, MetAP-1 and MetAP-2 
that exist in both endothelial and non-endothelial cell types. Fumagillin has 
been shown to bind and specifically inhibit MetAP-2. MetAP-2 is thought to 
be responsible for the cleavage of the amino-terminal methionine of proteins 
and peptides in a non-processive manner. However, in addition to this 
housekeeping role, MetAP-2 plays an ill-defined, yet critical role in the 
progression of the cell cycle; cells require either MetAP-1 or MetAP-2 for 
survival. It is unclear how the functions of MetAP-2 are related. A crystal 
structure of fumagillin bound to MetAP-2 has allowed a rational analysis of 
the molecular interactions that the molecule makes with the enzyme. The 
objective of this study is to determine whether the affinity for fumagillin 
binding to MetAP-2 can be decreased or eliminated by manipulation of these 
residues, without destroying the catalytic activity of the enzyme. By 
demonstrating that mutations can be made in MetAP-2 which decrease the 
affinity of fumagillin binding, a system can be developed in endothelial cells 
to test whether these mutations affect the anti-angiogenic properties of the 
drug. If these properties are indeed altered by mutations in MetAP-2, it 
constitutes significant evidence that the binding of fumagillin to MetAP-2 is a 
critical point in the molecular mechanism of the molecule's anti-angiogenic 
property. Thus this initial study may provide a starting point from which 
future detailed studies into the molecular mechanism of fumagillin action 
may be attempted. A detailed knowledge of the anti-angiogenic mechanism 
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may provide a framework generation of more potent, and highly clinically 
relevant anti-angiogenic agents. 
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PURPOSE OF STUDY AND HYPOTHESIS 
The purpose of this study is to identify mutations in the MetAP-2 gene 
that interfere with the binding of the anti-angiogenic agent fumagillin to this 
enzyme. Given that yeast require either MetAP-1 or MetAP-2 for growth, a 
yeast null Met-AP-1 strain (AMetAP-1) relies on functional MetAP-2 for 
growth. Fumagillin binds to and completely inhibits MetAP-2. Thus, a 
imitation that interferes with the binding of fumagillin to MetAP-2 is any 
mutation in MetAP-2 that allows a AMetAP-1 yeast strain to grow in an 
inhibitory concentration of fumagillin. That is, a mutation in MetAP-2 that 
rescues AMetAP-1 yeast from growth arrest when exposed to an inhibitory 
concentration of fumagillin must interfere with the binding of fumagillin to 
MetAP-2. 
The null hypothesis is that the affinity with which fumagillin binds to 
MetAP-2 cannot be decreased by identifying and mutating critical residues in 
the MetAP-2 enzyme using a rational approach. 
In order to test this hypothesis, the following specific aims are 
completed: 
1. Identification of mutations which are likely to interfere with binding 
2. Generation of the chosen mutations 
3. Incorporation of mutation into yeast strain 
4. Testing mutant yeast strain for ability to grow in an inhibitory 
concentration of fumagillin. 
Given the design of this study, the null hypothesis can be rejected by 
the identification of a mutation in MetAP-2 which allows yeast growth in the 
presence of fumagillin at an otherwise inhibitory concentration. 
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MATERIALS AND METHODS 
All experiments described below, including production of all reagents, 
were designed and performed by the author. 
Molecular modeling and selection of desired mutations 
Potential mutations were chosen by careful analysis of the crystal 
structure of fumagillin bound to MetAP-2. These potential mutations were 
modeled in MetAP-2 on a Silicon Graphics workstation running the O 
Graphics Molecular Modeling Program. The computer model was studied to 
predict the effect of the mutation on fumagillin binding. Mutations which 
appeared to cause steric hindrance thereby making fumagillin binding more 
difficult were chosen for use in the experiment. There is, however, currently 
no method of accurately predicting the impact of a given mutation in a 
protein to a binding partner. Thus, the information gleaned from the 
molecular modeling described here was simply used as a guideline for 
mutation selection, along with the crystal structure of the drug-enzyme 
complex. 
Site directed mutagenesis 
Mutations were made in the MetAP-2 enzyme by using site-directed 
mutagenesis, as described in the Stratagene QuickChange Site-Directed 
Mutagenesis Kit (Figure 6). This method involves the following steps: 
1. Preparation and synthesis of PCR Primers and wild type template 
2. PCR generation of Mutants 
3. Isolation of mutation 
4. Confirmation of mutation 
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1. PCR Primers and wild type template 
Primers containing the desired mutation flanked by wild type sequence 
were synthesized by the Keck Oligonucleotide Facility at Yale University. 
Primers were designed using guidelines of 25-40mers with >50% GC content, 
and a melting temperature, (Tm) >65°C (26). Desired mutations were located as 
close to the center of the primer as possible. Primers were synthesized in both 
forward and reverse orientations to allow annealing to either strand of the 
template DNA (Figure 7). In cases where multiple codon choices were 
available for a single amino acid given the degeneracy of the genetic code, the 
codon which is most frequently found in yeast to code for the intended amino 
acid was chosen, as reported in Current Protocols in Molecular Biology. The 
template plasmid pSE319 is a high-copy episomal plasmid which contains the 
entire wild type yeast MAP-2 sequence in addition to a replication origin, a trp 
gene, allowing yeast transformed with this plasmid to grow on tryptophan 
dropout plates, and an amp resistance gene, allowing for selection on 
ampicillin plates. Template DNA was isolated from archived bacteria using 
Qiagen QiaSpin Miniprep Kits. 
2. PCR Generation of mutant 
In order to achieve optimal ratios of template to primer, each PCR 
reaction was carried out using three different quantities of template: 6 ng, 12 
ng, 18 ng. Template was added to a reaction mix containing: lOmM dNTP, 
PCR reaction buffer (Stratagene), 125ng forward primer, 125 ng reverse 
primer, H20 for a final volume of 50 |iL. 1U PFU Turbo (Stratagene) was 
added to each tube. PCR was carried out in a MJ Research PCR machine using 
the following program: 
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Step 1. 95°C 
Step 2. 95°C 
30 sec 1 cycle 
30 sec 16 cycles 
60 sec 
15 minutes 1 cycle 
55°C 
Step 3. 68°C 
3. Isolation of mutant DNA 
Newly synthesized mutant DNA was isolated using the restriction 
endonuclease Dpn I (New England BioLabs). This enzyme is a frequent 
cutting restriction endonuclease which is highly specific for methylated DNA. 
This allows the enzyme to preferentially cut the methylated template DNA, 
while sparing the newly synthesized, unmethylated mutant gene. Restriction 
endonuclease reactions were performed by adding 1U of Dpn I directly to PCR 
reaction tube, gently mixing, and incubating for 1 hour at 37°C. 
4. Confirmation of mutation 
After digestion, 5 mL of sample was drawn from each reaction tube and 
loaded on a 0.9% agarose gel containing ethidium bromide. A standard lkb 
marker was used. Wild type pSE319 was used as a positive control. DNA from 
the positive reactions was sent to the Keck Oligonucleotide Facility at Yale 
University for sequencing and confirmation of incorporation of the desired 
mutation. Plasmids which were identified as carrying the desired mutation 
were used to transform a competent bacterial cell line (DH5a), using the 
following standard bacterial transformation protocol to provide a renewable 
source of plasmid. 
Bacterial Transformation Protocol 
Defrost frozen host cells in ice for 20 minutes 
Add PCR mix into tube and incubate 15 minutes on ice 
Heat shock host cells at 42°C for 45 seconds 
Return to ice for 20 minutes 
Add lmL LB medium to mix 
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Incubate at 37°C with shaking for 45-60 minutes 
Briefly centrifuge mixture and pour off supernatant 
Resuspend pellet in small remaining volume of LB 
Plate on LB/carbenicillin (50 mg/mL) plate 
Incubate for 16-20 hours at 37°C 
Yeast transformation 
Yeast require either MetAP-1 or MetAP-2 for viability. In order to 
exploit this requirement, a yeast null MetAP 1 strain (AMetAP-1) was used for 
transformation. This strain is S. cerevisiae strain W303 (MATa/MATa ade2- 
l/ade2-l his3-ll,15/his3-ll,15 Ieu2-3,112/leu2-3,112 ura3-l/ura3-l trpl-l/trpl- 
1 canl-100/canl-100) containing mapl::HIS3 disruption. Plasmids containing 
the desired mutant MetAP-2 gene were used to transform the AMetAP-1 yeast 
strain using the following standard Lithium Acetate yeast transformation 
protocol. Selection for transformants is accomplished by allowing the yeast to 
grow on tryptophan dropout plates. Since the vector harbors the tryptophan 
selection marker, yeast that grow on these plates are confirmed 
transformants. Single colonies are allowed to grow on these plates and are 
then selected for the viability assay. 
Yeast Lithium Acetate Transformation protocol 
Grow AMetAP-1 strain in YPD medium for 20-24 hours at 30°C 
Use 3mL saturated culture per transformation, transfer to Eppendorf 
tube 
Add lOmL per transformation salmon sperm carrier DNA 
Add 10 mL plasmid 
Vortex gently to mix 
Add 500mL transformation solution (100 mM Lithium Acetate, 40% 
PEG) 
Invert to mix 
Incubate at room temperature for 30 minutes 
Heat shock at 42°C for 12 minutes 
Briefly centrifuge and pour off supernatant 
Resuspend pellet in small remaining volume 
Plate on tryptophan dropout plate 
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Incubate 30°C for 4-6 days 
Selection of fumagillin resistant transformants 
Single colonies were picked from confirmed transformants from 
standard tryptophan dropout plates. These single colonies were then plated 
onto tryptophan dropout plates containing various concentrations of 
fumagillin: 0.2nm, lnm, 5nm, lOnm. The plates were allowed to incubate at 
30°C for 4-7 days and were monitored for growth. Wild type S. cerevisiae was 
used as a positive control on each plate, because it has a functional MetAP-1, 
which allows it to grow at all the test concentrations of fumagillin used in the 
study. AMetAP-1 yeast strain was used as a negative control on each plate, 
because it carries wild type MetAP-2, which is fully inhibited at all test 
concentrations of fumagillin used in the study. 
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RESULTS 
Rational Approach to Mutation Selection 
The initial objective in this study was to select a set of mutations in the 
MetAP-2 enzyme that might have the potential to reduce its binding affinity 
to fumagillin. This type of prediction can only be speculative; there is no 
current method for modeling a protein-protein interaction with 100% 
accuracy. Several amino acid residues in the enzyme were chosen for 
mutation. These residues are: His339, Phe219, Tyr444, Gly341(Figures 3,5). The 
His339 residue was chosen for mutation because of the important 
conformational change that occurs at this residue upon fumagillin binding: 
the imidazole side change swings out of the way to accommodate fumagillin 
binding (25). It was thought that replacement of this residue with an amino 
acid which has a bulky side chain that would not be able to change 
conformation might hinder fumagillin binding. The mutation H339F was 
therefore chosen as a study variable. (All mutations are notated using the 
standard one-letter amino acid code notation for the wild type amino acid, 
followed by the position in the protein sequence, followed by the one-letter 
code for the amino acid that was substituted in the mutant. For examle, 
H339F indicates that Histidine at position 339 in the wild type MetAP-2 gene 
was substituted to Phenylalanine in the mutant.) Additionally, the 
movement of this histidine imidazole side chain is allowed by the existence 
of a glycine residue, Gly341. By virtue of lacking a carbon containing side 
chain, this glycine residue ostensibly provides no additional steric resistance 
to the movement of the FIis339 side chain. For this reason, Gly341 was also 
chosen for mutation to several bulky residues: G341D, G341S, G341V, G341A, 
G341H. 
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The deep pocket, thought to be a specificity pocket, situated next to the 
active site of the enzyme may be important in discriminating the amino 
terminal methionine of the natural substrates of this enzyme. This pocket 
contains two residues, Phe219 and Tyr444, which were also chosen for 
mutation (Figures 3,5). These molecules are in particularly close proximity to 
fumagillin as demonstrated by the crystal structure, and form the mouth of 
the specificity pocket. The reactive epoxide of fumagillin, which forms the 
eventual covalent bond with MetAP-2, is contained in a side chain of 
fumagillin which protrudes into this specificity pocket. This occlusion of the 
pocket by mutations in these residues may hinder binding of the molecule as 
well. Additionally, Tyr444 is conserved in the MetAP-2 family across species, 
yet an analog is absent in the MetAP-1 family, which may explain some part 
of the inability of fumagillin to bind MetAP-1 (25). The mutations chosen 
were F219W, F219I, Y444W, Y444I. 
Site-directed mutagenesis 
Chosen mutations were made in the desired amino acid positions 
using site-directed mutagenesis. The PCR products of the desired mutations 
were run on an agarose electrophoresis gel for evidence of a PCR product. In 
those experiments that a product was seen, the PCR product was sent for 
sequencing for confirmation of the desired mutations. Desired sequences of 
all mutations were confirmed before transformation into AMetAP-1 yeast. 
Fumagillin Growth Assay 
The simplest way to determine whether the binding of fumagillin was 
functionally decreased as a result of the test mutation was to grow the yeast 
transformed with the desired mutation on test plates containing varying 
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concentrations of fumagillin. The concentrations used in this study were 0.2 
nM, 1 nM, 5nM, 10 nM. These values were chosen because they represent a 
range of concentrations which is known to inhibit growth of AMetAP-1 yeast 
strain while remaining non-toxic to wild type yeast. The results are shown in 
Figure 8. These results demonstrate three mutations, G341D, G341S, and 
H339F, which are resistant to lOnM, 5nM, and InM concentrations of 
fumagillin, respectively. 
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DISCUSSION 
Methionine Aminopeptidase-2 plays an important yet undefined role 
in the cell cycle of endothelial cells. Evidence exists which supports MetAP-2 
as a binding target of the anti-angiogenic agent fumagillin. It is unclear, 
however, how this interaction leads to growth arrest specifically in 
endothelial cells. MetAP-2 is known to have a housekeeping role in the cell 
which involves cleavage of the amino terminal methionine from many 
proteins and peptides. Biologically plausible mechanisms exist by which 
interruption of this function may lead to cell arrest, and evidence that either 
MetAP-1 or MetAP-2 function is required for cell survival lends additional 
support to this hypothesis. The N-end rule proposed by Varshavsky, et al. 
states that the stability of a cellular protein is determined in part by the 
penultimate amino-terminal residue (27). Thus MetAP-2 may play a role in 
regulating the stability of proteins. Alteration of the stability of a critical 
protein which is required for progression through the cell cycle may lead to 
arrest or growth dysregulation. Furthermore, MetAP-2 plays an important 
role in protein myristoylation. The covalent attachment of myristic acid to a 
glycine residue occurs in several important cell signaling proteins, such as 
certain tyrosine kinase family members, and cyclic AMP-dependent kinase, 
after the cleavage of the amino terminal methionine by a MetAP (28). 
Myristoylation has been shown to be required for signaling of several proteins 
(29). Thus, interruption of MetAP-2 activity may prevent myristoylation of 
some key signaling protein in endothelial cells which leads to growth arrest. 
An alternate explanation for fumagillin activity specifically on 
endothelial cells is that there is some other interaction in these cells which 
has not yet been demonstrated that is responsible for growth arrest. Given 
that MetAP-2 is a housekeeping enzyme which potentially binds many targets 
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in the cell, it is reasonable to question whether the molecular mechanism for 
the anti-angiogenic property of fumagillin is indeed related to its binding to 
this enzyme. The covalent bond formed between fumagillin and MetAP-2 
argues against a non-specific binding, but the drug may have some other 
important consequences in the cell which leads to growth arrest in 
endothelial cells, independent of its binding to MetAP-2. The objective of this 
study was to provide a starting point for demonstrating that the anti- 
angiogenic property of fumagillin is mediated through its binding to MetAP- 
2. The first step in this process was to determine whether the affinity with 
which fumagillin binds to MetAP-2 could be decreased by mutation of the 
enzyme. 
The approaches to determining whether MetAP-2 could be mutated to 
decrease its affinity for fumagillin include: 1. a rational approach, in which 
the molecular structure of the enzyme is studied for amino acids whose 
mutation would likely provide resistance for drug binding, or 2. a random 
approach, in which many mutations are made throughout the enzyme, and 
the viable mutations are selected and tested. In order to study the binding of 
fumagillin to MetAP-2, a rational approach was used. The concept of rational 
drug design involves carefully studying the structure of a molecule, and 
making only those changes which, based on that structure, have a 
scientifically plausible reason for attaining the desired goal. In this study, 
amino acid residues were changed based on either: 1. their proximity to 
relatively inflexible regions of the fumagillin molecule or 2. their 
determination of a specificity region of the enzyme as predicted by the crystal 
structure, with the intention of creating steric hindrances that decreased the 
affinity of the molecule for the enzyme which could not easily be 
compensated for by conformational change in the molecule. Likewise selected 
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residues were mutated to either large, inflexible, or polar amino acids to 
increase the chances of providing steric hindrance (such as phenylalanine, 
isoleucine, tryptophan, histidine, aspartic acid, and others). 
The benefit of this type of approach is that significant results may be 
achieved using a relatively small number of mutations, and those results 
have a plausible biologic explanation for achieving the desired goal. The 
drawback of this approach is that successful mutations which achieve the 
desired goal may be missed, because it would have been impossible to predict 
the effect those mutations would have had. 
It was expected at the outset of this project that the binding between 
MetAP-2 and fumagillin would be impossible to block completely given the 
highly stable covalent bond that is formed between the reactive epoxide of 
fumagillin and His231 of MetAP-2. Furthermore, this residue is thought to be 
critical to the catalytic activity of the enzyme, as an electrophile in an acid-base 
catalytic triad. Thus, mutation of this residue could potentially destroy the 
catalytic activity of the enzyme, but the covalent bond formed by this residue 
makes it unlikely that fumagillin binding can be blocked completely using 
other mutations in the enzyme. Flowever, a mutation which is found to 
decrease the affinity of fumagillin for MetAP-2, while not completely blocking 
its binding, would still prove useful in an endothelial cell system designed to 
study the relationship of fumagillin's binding to MetAP-2 and its anti- 
angiogenic property. That is, a clear decrease in anti-angiogenic potential of 
fumagillin associated with a mutation in an endothelial cell MetAP-2 known 
to decrease the affinity of fumagillin binding would conclusively demonstrate 
that the drug's mechanism is mediated via its binding to this enzyme. 
In order to select potential mutations for testing, the crystal structure of 
MetAP-2 bound to fumagillin was carefully studied. There are features of the 
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fumagillin binding site which prompted consideration for mutation 
selection. The first is the active site of the enzyme. The active site is formed by 
a deep pocket in the molecule with two cobalt molecules at its base. 
Additionally, there is a completely covered side pocket that may serve as a 
specificity pocket for the amino-terminal methionine side chain of the 
enzyme's natural substrates. This specificity pocket contains many residues 
which come into close proximity with fumagillin upon its binding to the 
enzyme. These include, but are not limited to Tyr444, His339, and Phe219 
(Figures 3,5). These residues were chosen for mutation based on these close 
hydrophobic contacts, and the fact that they were not known to be critical for 
the enzyme function. The mutations chosen were F219I, F219W, Y444I, 
Y444W. 
The second feature of the drug-bound enzyme that was of interest was 
the residue FIis339. This is the only residue in the enzyme which undergoes 
significant motion upon fumagillin binding (25). The imidazole side chain of 
this residue rotates upon fumagillin binding to avoid close contacts with 
fumagillin. It was thought that substitution of an amino acid containing a 
side chain less able to perform this rotation might be a useful mutation. 
Mutation to phenylalanine was thus attempted. Additionally, there is a 
glycine residue, Gly341, which is positioned behind His339, which potentially 
provides space to accept the rotation of the His339 side chain upon fumagillin 
binding due to its lack of a side chain. It was believed that replacement of this 
residue with a bulkier residue might also inhibit the rotation of FIis339 and 
therefore decrease fumagillin binding affinity. The mutations chosen were 
thus H339F, G341S, G341V, G341A, G341D, G341H. 
In order to generate the chosen mutations in the yeast MetAP-2 gene, a 
site directed mutagenesis approach was used. In this approach, a 
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oligonucleotide containing the desired mutation is synthesized, with several 
bases of wild type sequence flanking it on either side. This oligonucleotide, 
typically a 40-50mer synthesized in both forward and reverse orientations, is 
used as a primer for a PCR, using the wild type gene contained in a plasmid as 
a template. After several successive rounds of PCR, a plasmid containing the 
desired mutation is generated. The wild type DNA is then digested using a 
frequent cutting endonuclease which is highly selective for methylated DNA. 
In this fashion, the newly synthesized, non-methylated DNA is spared, while 
the template plasmid, which had been harvested from bacterial culture and 
thus methylated, is destroyed (Figure 6). Representative samples of successful 
PCR reactions, as demonstrated by the appearance of a band at the expected 
molecular weight on an agarose gel, were then selected and sequenced for 
confirmation of incorporation of the correct mutation. 
Confirmed mutants were then used to transform a AMetAP-1 yeast 
strain. Use of this strain enabled the simplification of the assay for fumagillin 
binding. Given that yeast are dependent on either functional MetAP-1 or 
MetAP-2 for growth, a AMetAP-1 strain is dependent entirely on functional 
MetAP-2. Thus, a simple growth assay can be used to test the effect of the test 
mutations on fumagillin binding. That is, when MetAP-2 is bound and 
inhibited by fumagillin, the yeast strain will no longer grow, resulting in a 
lack of visible colonies on a fumagillin plate. In cases where the mutated 
MetAP-2 is more resistant to binding than wild type, a higher concentration 
of fumagillin is required to arrest the yeast strain, resulting in visible colonies 
on fumagillin plates at concentrations that would inhibit growth of the wild 
type strain. In the theoretical case in which fumagillin binding is totally 
blocked by a test mutation, the yeast strain should grow on plates any 
concentration of fumagillin. The concentrations used for experimentation in 
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this study were 0.2nM, InM, 5nM, and lOnM. These concentrations have been 
shown previously in the Crews Laboratory to inhibit growth of AMetAP-1 
yeast containing wild type MetAP-2. 
Figure 8 shows the results from the initial test mutations. Seven of the 
ten attempted mutations displayed no resistance to growth inhibition by 
fumagillin. It is expected that these mutations which are designed to increase 
steric hindrance of fumagillin binding may be compensated for by small shifts 
in the conformation of either the protein or the drug molecule. There is no 
current means of accurately predicting this type of small conformational shift. 
Test mutations G341D, G341S and H339F displayed resistance to growth 
inhibition by fumagillin above wild type at lOnM, 5nM and InM, 
respectively. The decreased potency of fumagillin in these cases can be 
attributed to decreased affinity of binding due to steric limitations imposed by 
the test mutation, since this is the only variable changed with respect to wild 
type. AMetAPl yeast containing wild type MetAP-2 did not grow at 0.2nm, 
InM, 5nM, or lOnM concentration of fumagillin, confirming that these 
concentrations fall within a range that fully inhibits wild type MetAP-2. The 
findings presented here confirm the hypothesis that generation of specific 
mutations in MetAP-2 can interfere with fumagillin binding. 
The results presented in this study demonstrate that it is possible to 
interfere to some extent the binding of fumagillin to MetAP-2. Although it 
has not been possible in this study to completely block binding of fumagillin 
to MetAP-2, this may be due in part to the highly stable interaction that is the 
result of the formation of a covalent bond between the enzyme and the 
reactive epoxide of the drug. Flowever, the significance of the mutations that 
have been found to decrease binding affinity is in providing a basis for testing 
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the relationship between the binding of fumagillin to MetAP-2 and its anti- 
angiogenic potential. 
The next experiment that needs to be done to this end is the stable 
incorporation of the mutations described above into an endothelial cell line. 
By overexpressing a fumagillin resistant MetAP-2 mutant in an endothelial 
cell line, a link can be established between the anti-angiogenic property of the 
drug and its binding to this enzyme. That is, if endothelial cells can be rescued 
from fumagillin-induced growth arrest by a mutation in MetAP-2 that is 
known to decrease fumagillin binding, it would be clearly demonstrated that 
the anti-angiogenic property of fumagillin is mediated through its interaction 
with the enzyme. This would exclude the possibility that the specific actions 
of fumagillin on endothelial cells relies on some other function of the drug 
in endothelial cells that is different that its action in most cells, its interaction 
with MetAP-2. Initial attempts were made to introduce this mutation into a 
Bovine Aortic Endothelial Cell (BAEC) line using standard methods, but 
these attempts have been thus far unsuccessful. Alternate methods are 
currently under consideration to accomplish this goal. 
Other experimentation that could prove useful in the framework of 
this experiment include the combination of several successful single 
mutations to generate a set of mutations which together result in increased 
effectiveness at blocking fumagillin binding. Initial experiments to this end 
were performed, but none showed any benefit above the single mutations. 
Other combinations may, however, prove useful. Additionally, the His231 
residue of the enzyme can be mutated. This residue is responsible for the 
formation of the covalent bond between fumagillin and MetAP-2 and is 
thought to be a critical residue in the catalytic mechanism of the enzyme. 
Although it is likely that mutation of this residue will result in a non- 
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functional enzyme, confirmation of this by generation of this mutation 
would complete this study. 
The significance of the data presented in this study lie mainly in that 
they provide a basis for which future significant research can be conducted. As 
described previously, the mutations which have been shown to be effective in 
reducing the binding of fumagillin to MetAP-2 can now be transferred to an 
endothelial cell system to determine whether the anti-angiogenic effects of 
the drug are mediated by its interaction with this enzyme. This is a critical 
piece of information in the delineation of the molecular mechanism of this 
drug. A clear understanding of the molecular mechanism of this anti- 
angiogenic agent may allow the generation of more potent, less toxic agents, 
by identifying new molecular targets. Understanding the molecular basis of 
this growth pathway in endothelial calls may also provide valuable insights 
to basic endothelial cell biology, which can have important ramifications to 
tumor and vascular biology. 
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Compound 
Fumagillin 
TNP-470 
Structure 
O O 
Figure 1. Molecular structure of fumagillin. The chemical structure of the 
anti-angiogenic agent fumagillin is shown, along with its derivative, TNP-470 
(16). Reprinted with permission. 

Figure 2. Overall structure of MetAP-2 bound to fumagillin. MetAP-2 (shown 
in red, green, light blue) is characterized by 7 a helices and 9 (3 sheets. 
Fumagillin (shown in yellow and red ball and stick) binds in the active site of 
the enzyme. The two cobalt molecules (shown in dark blue) are partially 
obstructed by fumagillin (25). Reprinted with permission. 
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Figure 3. Fumagillin binding causes a conformational change in H339. A 
portion of the active site of native MetAP-2 is shown in blue. Fumagillin 
(black and red) bound to MetAP-2 is shown in yellow. A conformational 
change takes place, shifting the position of the imidazole side chain of 
His339). Other close contacts are labeled using the one letter amino acid code 
and a number indicating position in the primary structure. (Figure generated 
with the assistance of Mark Briedenbach). 
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Figure 4. Fumagillin in the active site of MetAP-2. Fumagillin and the 
covalently attached His231 are shown as ball and stick with carbon yellow, 
oxygen red, and nitrogen blue. Side chains that interact with fumagillin are 
drawn as sticks, either in green (native protein) or blue (drug-bound protein) 
(25). Reprinted with permission. 
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Figure 5. Close side chain contacts to fumagillin in the binding pocket of 
MetAP-2. Black dashed lines indicate hydrogen bonds, red radial lines indicate 
hydrophobic contacts. Wat= water molecule, Co= cobalt molecule (25). 
Reprinted with permission. 
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Figure 6. Site-Directed Mutagenesis. Template DNA containing the desired 
target gene is shown. A primer is designed containing the desired mismatch. 
The PCR reaction is carried out, using the plasmid as a template. The original 
DNA is digested using Dpn I, leaving only the synthesized DNA containing 
the desired mutation. DH5-a competent bacteria were used in this study. 
Figure reproduced from Stratagene QuickChange Site Directed Mutagenesis 
Manual. 
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Mutation 
F219I 
F219W 
Y444I 
Y444W 
G341D 
G341S 
G341V 
G341A 
G341H 
H339F 
Forward (51 to3') Primer 
gga gga tcc caa ate tea agg tat tgg gat tcc aac ggg tet c 
gga gga tcc caa ate tea agg tat tgg gtg gee aac ggg tet c 
egg ttt agt aca gga tat tcc ace att gaa ega tat ccc egg 
egg ttt agt aca gga ttg gee ace att gaa ega tat ccc egg 
c gca cca tat cgt ate cac ggc gat aaa tcc gtt ccc 
c gca cca tat cgt ate cac ggc agt aaa tcc gtt ccc 
gca cca tat cgt ate cac ggc gtt aaa tcc gtt ccc ate 
gca cca tat cgt ate cac ggc get aaa tcc gtt ccc ate 
gca cca tat cgt ate cac ggc cat aaa tcc gtt ccc ate 
gta teg cac cat ate gta tet teg geg gta aat ccg 
Figure 7. Primers used in Site Directed Mutagenesis. Forward (5' to 3 ) 
sequence of the primer used in site directed mutagenesis are listed. Reverse 
primers used are the reverse complements of the sequences listed above. 
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Mutation Trp- Fg 
F219I + 0 
F219W + 0 
Y444I + 0 
Y444W + 0 
G341D + lOnM 
G341S + 5nM 
G341V + 0 
G341A + 0 
G341H + 0 
H339F + InM 
Figure 8. Growth of test mutations on fumagillin. Mutations tested are listed. 
The second column (Trp-) indicates growth on tryptophan dropout plates. 
The third column (Fg) indicates the highest concentration of fumagillin on 
which the strain grew. 
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